The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

Abstract The SARS-CoV-2 Omicron variant (B. 1.1. 529) has multiple spike protein
mutations, that contribute to viral escape from antibody neutralization,,–and reduce vaccine …

Currently, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread
worldwide as an Omicron variant. This variant is a heavily mutated virus and designated as …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B. 1.1. 529)
variant is highly transmissible with potential immune escape. We conducted a test-negative …

We address whether T cell responses induced by different vaccine platforms (mRNA-1273,
BNT162b2, Ad26. COV2. S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 …

The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …

Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of
its increased transmissibility and its numerous spike mutations, which have the potential to …